Bond.az White LogoBond.az Black Logo

Morgan Stanley Backs AppLovin on Conversion Growth

Morgan Stanley reiterates Overweight on AppLovin with $720 target, highlighting conversion growth potential and strong Q1 results.

Sophia Anderson
BySophia Anderson- Senior Editor
|
0

Morgan Stanley reiterated an Overweight rating on AppLovin Corp (NASDAQ:APP) with a $720.00 price target. The company, valued at $172.75 billion, has shown exceptional growth with revenue surging 66% over the last twelve months to $6.16 billion.

The firm said AppLovin can sustain above-market growth by expanding its conversion rate, as approximately 99% of its ads still do not generate a conversion. A 10x conversion rate gap exists between AppLovin and market leaders, implying significant headroom.

Improvements would stem from scale and data advantages, continued mix shift into non-endemic ads, and lower repeat rates. AppLovin's conversion rate has expanded 30 basis points over the last 18 months. Each additional 10 basis points would drive 17 points of net revenue growth.

If AppLovin maintains 20 basis points of annual conversion rate expansion, it could see revenue and EBITDA approximately 50% above consensus by 2030, putting Morgan Stanley's $1,100 bull case in play. The company's impressive 88% gross profit margin supports its ability to invest in conversion optimization.

In recent news, AppLovin reported strong Q1 2026 results, beating earnings and revenue forecasts. EPS of $3.56 exceeded the expected $3.42, while revenue of $1.84 billion topped the forecast of $1.78 billion. Several analysts raised price targets, including Piper Sandler ($665), Wolfe Research ($580), Goldman Sachs ($585), and Jefferies ($700).

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
731

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...